| scholarly article | Q13442814 |
| P50 | author | Celia Greenwood | Q55458850 |
| P2093 | author name string | D Schadendorf | |
| L C van Kempen | |||
| A Spatz | |||
| J Jarry | |||
| P2860 | cites work | MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis | Q57947473 |
| miR-21 Regulates Skin Wound Healing by Targeting Multiple Aspects of the Healing Process | Q62578008 | ||
| miR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non-small Cell Lung Cancer | Q63253996 | ||
| Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer | Q83121081 | ||
| Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer | Q83603532 | ||
| Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis | Q84071421 | ||
| Decreased serum miR-181a is a potential new tool for breast cancer screening | Q84365031 | ||
| Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer | Q84484734 | ||
| Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis | Q84582500 | ||
| Evidence for serum miR-15a and miR-16 levels as biomarkers that distinguish sepsis from systemic inflammatory response syndrome in human subjects | Q84742084 | ||
| MiR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma | Q84949141 | ||
| Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor | Q84963968 | ||
| MiRNA‐199a‐3p: A potential circulating diagnostic biomarker for early gastric cancer | Q86892940 | ||
| Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer | Q95383732 | ||
| Low Levels of Cell-Free Circulating miR-361-3p and miR-625* as Blood-Based Markers for Discriminating Malignant from Benign Lung Tumors | Q21134548 | ||
| Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers | Q21195201 | ||
| Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer | Q21245710 | ||
| Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development | Q22000752 | ||
| Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer | Q24609577 | ||
| MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer | Q24632636 | ||
| Circulating microRNAs as stable blood-based markers for cancer detection | Q24652098 | ||
| GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer | Q28296081 | ||
| The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities | Q28297958 | ||
| An Empirical Evaluation of normalization Methods for MicroRNA Arrays in a Liposarcoma Study | Q28396443 | ||
| Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma | Q29614238 | ||
| Controlling the false discovery rate in behavior genetics research | Q29614833 | ||
| Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies | Q29614926 | ||
| Replication validity of genetic association studies | Q29615456 | ||
| The MicroRNA Spectrum in 12 Body Fluids | Q29618068 | ||
| MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. | Q30541314 | ||
| miRDeep*: an integrated application tool for miRNA identification from RNA sequencing data | Q30580665 | ||
| Comparing the MicroRNA spectrum between serum and plasma | Q31080442 | ||
| Detection of cancer with serum miRNAs on an oligonucleotide microarray | Q33481633 | ||
| Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy | Q33572407 | ||
| Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. | Q33579721 | ||
| A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer | Q33742015 | ||
| Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs | Q34002982 | ||
| Haemolysis during sample preparation alters microRNA content of plasma. | Q34016595 | ||
| SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer | Q34071777 | ||
| Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. | Q34123686 | ||
| Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma | Q34151439 | ||
| Circulating microRNAs (miRNA) in serum of patients with prostate cancer | Q34182161 | ||
| Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer | Q34202973 | ||
| Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease | Q34230017 | ||
| Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer | Q34240615 | ||
| Evaluation of normalization methods in mammalian microRNA-Seq data | Q34244842 | ||
| Analysis of serum genome-wide microRNAs for breast cancer detection. | Q34258421 | ||
| Blood Cell Origin of Circulating MicroRNAs: A Cautionary Note for Cancer Biomarker Studies | Q34291952 | ||
| Plasma miR-601 and miR-760 Are Novel Biomarkers for the Early Detection of Colorectal Cancer | Q34412367 | ||
| Serum microRNA-155 as a potential biomarker to track disease in breast cancer | Q34447755 | ||
| Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients | Q34496664 | ||
| Circulating microRNAs as specific biomarkers for breast cancer detection. | Q34542335 | ||
| Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. | Q34559564 | ||
| Dampening Enthusiasm for Circulating MicroRNA in Breast Cancer | Q34614489 | ||
| Identification and evaluation of plasma microRNAs for early detection of colorectal cancer | Q34729935 | ||
| Plasma Processing Conditions Substantially Influence Circulating microRNA Biomarker Levels | Q34769479 | ||
| BR-squared: a practical solution to the winner's curse in genome-wide scans | Q34779086 | ||
| Limit of blank, limit of detection and limit of quantitation | Q34852018 | ||
| Influence of plasma processing on recovery and analysis of circulating nucleic acids | Q35035846 | ||
| Plasma microRNAs as potential biomarkers for non-small-cell lung cancer | Q35087819 | ||
| Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma | Q35108381 | ||
| Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome | Q35802426 | ||
| Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma | Q35879824 | ||
| Changes in circulating microRNA levels associated with prostate cancer | Q35879858 | ||
| miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status | Q36403453 | ||
| Plasma MicroRNAs as Novel Biomarkers for Endometriosis and Endometriosis-Associated Ovarian Cancer | Q36679982 | ||
| Non-replication of association studies: "pseudo-failures" to replicate? | Q36851908 | ||
| Identification of serum microRNA profiles in colon cancer | Q36889636 | ||
| Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort | Q36997902 | ||
| Serum circulating microRNA profiling for identification of potential breast cancer biomarkers | Q37260646 | ||
| Quantification of small non-coding RNAs allows an accurate comparison of miRNA expression profiles. | Q37327967 | ||
| Interpretation of tests of heterogeneity and bias in meta-analysis | Q37329334 | ||
| Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients | Q37394399 | ||
| Centrifugation: an important pre-analytic procedure that influences plasma microRNA quantification during blood processing | Q37409781 | ||
| Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer | Q38675709 | ||
| miR‐16 inhibits cell proliferation by targeting IGF1R and the Raf1–MEK1/2–ERK1/2 pathway in osteosarcoma | Q39178990 | ||
| Clinical impact of serum exosomal microRNA‐21 as a clinical biomarker in human esophageal squamous cell carcinoma | Q39229733 | ||
| Downregulation of miR-145 associated with cancer progression and VEGF transcriptional activation by targeting N-RAS and IRS1. | Q39234760 | ||
| Circulating microRNAs as novel minimally invasive biomarkers for breast cancer | Q39281588 | ||
| miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma | Q39291006 | ||
| miRNA expression profiling for identification of potential breast cancer biomarkers | Q39347477 | ||
| Determination of plasma microRNA for early detection of gastric cancer. | Q39508309 | ||
| Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer | Q39550421 | ||
| MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease | Q39950193 | ||
| Circulating microRNAs in plasma of patients with gastric cancers | Q39986294 | ||
| Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). | Q41875540 | ||
| miRNA-Seq normalization comparisons need improvement | Q42157855 | ||
| MIQE précis: Practical implementation of minimum standard guidelines for fluorescence-based quantitative real-time PCR experiments | Q42409958 | ||
| Validation of extraction methods for total RNA and miRNA from bovine blood prior to quantitative gene expression analyses | Q43748056 | ||
| PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis | Q43827753 | ||
| Down-regulation of miRNA-30a in human plasma is a novel marker for breast cancer | Q43873674 | ||
| A panel of five circulating microRNAs as potential biomarkers for prostate cancer | Q44430269 | ||
| microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers | Q44586065 | ||
| Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. | Q44725222 | ||
| Diagnostic microRNA markers to screen for sporadic human colon cancer in blood | Q47381718 | ||
| The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors | Q50496294 | ||
| Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study | Q50498335 | ||
| Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer | Q51535040 | ||
| Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours | Q52843051 | ||
| A flexible genome‐wide bootstrap method that accounts for rankingand threshold‐selection bias in GWAS interpretation and replication study design | Q53083865 | ||
| miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF | Q53262839 | ||
| Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening | Q53416418 | ||
| A plasma microRNA panel for early detection of colorectal cancer | Q54270072 | ||
| Circulating microRNAs as novel biomarkers for platelet activation. | Q54277423 | ||
| Circulating miRNA is a novel marker for head and neck squamous cell carcinoma. | Q54300178 | ||
| Serum microRNA‐21 is a novel biomarker in patients with esophageal squamous cell carcinoma | Q54322917 | ||
| Analysis of circulating microRNA: preanalytical and analytical challenges. | Q54378210 | ||
| Primer sequence disclosure: a clarification of the MIQE guidelines. | Q54382127 | ||
| Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. | Q54456800 | ||
| P433 | issue | 4 | |
| P921 | main subject | microRNA | Q310899 |
| P304 | page(s) | 819-829 | |
| P577 | publication date | 2014-03-06 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Molecular Oncology | Q2190736 |
| P1476 | title | The validity of circulating microRNAs in oncology: five years of challenges and contradictions | |
| P478 | volume | 8 |
| Q55691041 | A Direct Plasma miRNA Assay for Early Detection and Histological Classification of Lung Cancer. |
| Q41093183 | A MicroRNA Panel in Pancreatic Cyst Fluid for the Risk Stratification of Pancreatic Cysts in a Prospective Cohort |
| Q36107509 | A comparison between quantitative PCR and droplet digital PCR technologies for circulating microRNA quantification in human lung cancer. |
| Q39412220 | Absolute Measurement of Cardiac Injury-Induced microRNAs in Biofluids across Multiple Test Sites |
| Q35987412 | Absolute quantification of cell-free microRNAs in cancer patients |
| Q47685860 | Application of Individual qPCR Performance Parameters for Quality Control of Circulating MicroRNA Data |
| Q26775704 | Can circulating miRNAs live up to the promise of being minimal invasive biomarkers in clinical settings? |
| Q55428812 | Circulating MicroRNA Biomarkers in Melanoma: Tools and Challenges in Personalised Medicine. |
| Q40388823 | Circulating MicroRNA Quantification Using DNA-binding Dye Chemistry and Droplet Digital PCR. |
| Q42090777 | Circulating Neutrophil MicroRNAs as Biomarkers for the Detection of Lung Cancer |
| Q38940611 | Circulating Non-coding RNA as Biomarkers in Colorectal Cancer |
| Q26745985 | Circulating biomarkers to monitor cancer progression and treatment |
| Q26830329 | Circulating glioma biomarkers |
| Q55378766 | Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. |
| Q90664794 | Circulating miRNAs as Biomarker in Cancer |
| Q41763210 | Circulating microRNAs as Candidate Biomarkers for the Surveillance of Melanoma Patients |
| Q26767346 | Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma |
| Q55361312 | Circulating microRNAs as Prognostic and Predictive Biomarkers in Patients with Colorectal Cancer. |
| Q35562931 | Circulating microRNAs as potential biomarkers for endometriosis |
| Q93109146 | Clinical Translatability of "Identified" Circulating miRNAs for Diagnosing Breast Cancer: Overview and Update |
| Q38795294 | Clinical significance of circulating miRNA detection in lung cancer |
| Q54203619 | Clinical utility of circulating non-coding RNAs - an update |
| Q35828512 | Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer? |
| Q35137273 | Critical analysis of the potential for microRNA biomarkers in breast cancer management. |
| Q28072364 | Current Technologies and Recent Developments for Screening of HPV-Associated Cervical and Oropharyngeal Cancers |
| Q35789307 | Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR. |
| Q36101421 | Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer |
| Q48193333 | Differentially expressed miRNAs in trisomy 21 placentas |
| Q55497327 | Droplet digital PCR-based circulating microRNA detection serve as a promising diagnostic method for gastric cancer. |
| Q55277056 | Effects of Acute Aerobic Exercise on Rats Serum Extracellular Vesicles Diameter, Concentration and Small RNAs Content. |
| Q89749656 | Emergence of Circulating MicroRNAs in Breast Cancer as Diagnostic and Therapeutic Efficacy Biomarkers |
| Q88758254 | Epilepsy biomarkers - Toward etiology and pathology specificity |
| Q33905628 | Evaluation and diagnostic potential of circulating extracellular vesicle-associated microRNAs in adrenocortical tumors. |
| Q55418749 | Evaluation of commercially available small RNASeq library preparation kits using low input RNA. |
| Q47139209 | Evidence that circulating proteins are more promising than miRNAs for identification of patients with squamous cell carcinoma of the tongue. |
| Q93049153 | Exo-miRNAs as a New Tool for Liquid Biopsy in Lung Cancer |
| Q53520277 | Exosomal MicroRNA-15a Transfer from the Pancreas Augments Diabetic Complications by Inducing Oxidative Stress |
| Q52766495 | Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression |
| Q40764983 | Gastric adenocarcinoma microRNA profiles in fixed tissue and in plasma reveal cancer-associated and Epstein-Barr virus-related expression patterns |
| Q54939965 | Identification of Thyroid-Associated Serum microRNA Profiles and Their Potential Use in Thyroid Cancer Follow-Up. |
| Q50321693 | Integrating Circulating Immunological and Sputum Biomarkers for the Early Detection of Lung Cancer |
| Q48509845 | Intra-individual variation of miRNA expression levels in human plasma samples |
| Q38700529 | Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients |
| Q57267891 | Methods for Biomarker Analysis |
| Q90456132 | MicroRNA Ratios Distinguish Melanomas from Nevi |
| Q35198177 | MicroRNA-derived fragment length polymorphism assay |
| Q38667013 | MicroRNAs and Gastrointestinal Stromal Tumor |
| Q47947610 | MicroRNAs as biomarkers for clinical studies |
| Q90429127 | MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside |
| Q38580491 | Micromarkers 2.0: an update on the role of microRNAs in cancer diagnosis and prognosis. |
| Q90149240 | Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia |
| Q40219210 | OncomiR detection in circulating body fluids: a PDMS microdevice perspective |
| Q30491447 | Plasma Micro-RNA Alterations Appear Late in Pancreatic Cancer |
| Q41621167 | Prediction of miRNA-disease Associations using an Evolutionary Tuned Latent Semantic Analysis. |
| Q36953740 | Prediction of miRNA-disease associations with a vector space model |
| Q47728281 | Role of micro-RNAs in breast cancer surgery. |
| Q42317085 | Serum microRNA profiling in patients with glioblastoma: a survival analysis |
| Q49587519 | Serum microRNA-193b as a promising biomarker for prediction of chemoradiation sensitivity in esophageal squamous cell carcinoma patients |
| Q57800908 | Super-resolution Geometric Barcoding for Multiplexed miRNA Profiling |
| Q91045245 | The 14q32 maternally imprinted locus is a major source of longitudinally stable circulating microRNAs as measured by small RNA sequencing |
| Q89511639 | The miRNAs Role in Melanoma and in Its Resistance to Therapy |
| Q34177547 | The potential of microRNAs in personalized medicine against cancers |
| Q41954466 | Towards a new standardized method for circulating miRNAs profiling in clinical studies: Interest of the exogenous normalization to improve miRNA signature accuracy |
| Q39394558 | Translating cancer epigenomics into the clinic: focus on lung cancer |
| Q34324228 | Tumor surveillance by circulating microRNAs: a hypothesis |
| Q55379182 | miR-19 in blood plasma reflects lung cancer occurrence but is not specifically associated with radon exposure. |
| Q28078451 | miRNA expression and function in thyroid carcinomas: a comparative and critical analysis and a model for other cancers |
| Q92923058 | miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis |
| Q42156325 | microRNAs Make the Call in Cancer Personalized Medicine. |
| Q38668239 | microRNAs and Personalized Medicine: Evaluating Their Potential as Cancer Biomarkers |
Search more.